Tag Archives: Surrogate Endpoints

Why Does The FDA Approve Cancer Drugs That Don’t Work

BRIAN KLEPPER Posted 10/23/15 on The Health Care Blog A new study in JAMA Internal Medicine finds that two-thirds of cancer drugs considered by the US Food and Drug Administration (FDA) over the past five years were approved without evidence that … Continue reading

Rate this:

Posted in Analytics, Brian Klepper, Conflicts of Interest, Health Care Cost, Innovation, Life Sciences, Market Dynamics, Policy/Law/Regulation | Tagged , , | 3 Comments